These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37300425)

  • 21. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
    Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
    Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines.
    Dickey TH; Ma R; Orr-Gonzalez S; Ouahes T; Patel P; McAleese H; Butler B; Eudy E; Eaton B; Murphy M; Kwan JL; Salinas ND; Holbrook MR; Lambert LE; Tolia NH
    Cell Rep; 2023 Mar; 42(3):112266. PubMed ID: 36943870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern.
    Lee IJ; Lan YH; Wu PY; Wu YW; Chen YH; Tseng SC; Kuo TJ; Sun CP; Jan JT; Ma HH; Liao CC; Liang JJ; Ko HY; Chang CS; Liu WC; Ko YA; Chen YH; Sie ZL; Tsung SI; Lin YL; Wang IH; Tao MH
    Emerg Microbes Infect; 2023 Dec; 12(1):2149353. PubMed ID: 36395071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
    Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
    Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.
    Walls AC; Fiala B; Schäfer A; Wrenn S; Pham MN; Murphy M; Tse LV; Shehata L; O'Connor MA; Chen C; Navarro MJ; Miranda MC; Pettie D; Ravichandran R; Kraft JC; Ogohara C; Palser A; Chalk S; Lee EC; Guerriero K; Kepl E; Chow CM; Sydeman C; Hodge EA; Brown B; Fuller JT; Dinnon KH; Gralinski LE; Leist SR; Gully KL; Lewis TB; Guttman M; Chu HY; Lee KK; Fuller DH; Baric RS; Kellam P; Carter L; Pepper M; Sheahan TP; Veesler D; King NP
    Cell; 2020 Nov; 183(5):1367-1382.e17. PubMed ID: 33160446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of a silica nanoparticle-based SARS-CoV-2 vaccine in mice.
    Barbey C; Su J; Billmeier M; Stefan N; Bester R; Carnell G; Temperton N; Heeney J; Protzer U; Breunig M; Wagner R; Peterhoff D
    Eur J Pharm Biopharm; 2023 Nov; 192():41-55. PubMed ID: 37774890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.
    Gattinger P; Kratzer B; Tulaeva I; Niespodziana K; Ohradanova-Repic A; Gebetsberger L; Borochova K; Garner-Spitzer E; Trapin D; Hofer G; Keller W; Baumgartner I; Tancevski I; Khaitov M; Karaulov A; Stockinger H; Wiedermann U; Pickl WF; Valenta R
    Allergy; 2022 Aug; 77(8):2431-2445. PubMed ID: 35357709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.
    Kim YI; Kim D; Yu KM; Seo HD; Lee SA; Casel MAB; Jang SG; Kim S; Jung W; Lai CJ; Choi YK; Jung JU
    mBio; 2021 Mar; 12(2):. PubMed ID: 33653891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.
    Ellis D; Brunette N; Crawford KHD; Walls AC; Pham MN; Chen C; Herpoldt KL; Fiala B; Murphy M; Pettie D; Kraft JC; Malone KD; Navarro MJ; Ogohara C; Kepl E; Ravichandran R; Sydeman C; Ahlrichs M; Johnson M; Blackstone A; Carter L; Starr TN; Greaney AJ; Lee KK; Veesler D; Bloom JD; King NP
    Front Immunol; 2021; 12():710263. PubMed ID: 34267764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice.
    Sun W; He L; Zhang H; Tian X; Bai Z; Sun L; Yang L; Jia X; Bi Y; Luo T; Cheng G; Fan W; Liu W; Li J
    Signal Transduct Target Ther; 2021 Sep; 6(1):340. PubMed ID: 34504054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
    Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
    mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody cocktail effective against variants of SARS-CoV-2.
    Liang KH; Chiang PY; Ko SH; Chou YC; Lu RM; Lin HT; Chen WY; Lin YL; Tao MH; Jan JT; Wu HC
    J Biomed Sci; 2021 Nov; 28(1):80. PubMed ID: 34814920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection.
    Geng Q; Tai W; Baxter VK; Shi J; Wan Y; Zhang X; Montgomery SA; Taft-Benz SA; Anderson EJ; Knight AC; Dinnon KH; Leist SR; Baric RS; Shang J; Hong SW; Drelich A; Tseng CK; Jenkins M; Heise M; Du L; Li F
    PLoS Pathog; 2021 Sep; 17(9):e1009897. PubMed ID: 34492082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three in one: An effective and universal vaccine expressing heterologous tandem RBD trimer by rabies virus vector protects mice against SARS-CoV-2.
    Huang J; Wang W; Li H; Bai Y; Song Y; Jiao C; Jin H; Huang P; Zhang H; Xia X; Yan F; Li Y; Wang H
    Antiviral Res; 2024 Jul; 227():105905. PubMed ID: 38740191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.
    Conforti A; Marra E; Palombo F; Roscilli G; Ravà M; Fumagalli V; Muzi A; Maffei M; Luberto L; Lione L; Salvatori E; Compagnone M; Pinto E; Pavoni E; Bucci F; Vitagliano G; Stoppoloni D; Pacello ML; Cappelletti M; Ferrara FF; D'Acunto E; Chiarini V; Arriga R; Nyska A; Di Lucia P; Marotta D; Bono E; Giustini L; Sala E; Perucchini C; Paterson J; Ryan KA; Challis AR; Matusali G; Colavita F; Caselli G; Criscuolo E; Clementi N; Mancini N; Groß R; Seidel A; Wettstein L; Münch J; Donnici L; Conti M; De Francesco R; Kuka M; Ciliberto G; Castilletti C; Capobianchi MR; Ippolito G; Guidotti LG; Rovati L; Iannacone M; Aurisicchio L
    Mol Ther; 2022 Jan; 30(1):311-326. PubMed ID: 34547465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.